300683 海特生物
按盤價 
25.780 -3.320 (-11.409%)
25.780 -3.320 (-11.409%) | 2026/06 - 中期 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -3.710 | -10.160 | -2.848 | -5.046 | -0.605 |
| 總資產報酬率 ROA (%) | -3.118 | -8.390 | -2.348 | -4.256 | -0.519 |
| 投入資產回報率 ROIC (%) | -3.487 | -9.445 | -2.617 | -4.602 | -0.554 | 邊際利潤分析 |
| 銷售毛利率 (%) | 34.247 | 42.641 | 42.846 | 42.709 | 48.465 |
| 營業利潤率 (%) | -36.858 | -43.237 | -11.666 | -23.755 | -0.991 |
| 息稅前利潤/營業總收入 (%) | -39.469 | -44.969 | -13.140 | -26.421 | -2.769 |
| 淨利潤/營業總收入 (%) | -35.425 | -43.481 | -11.367 | -21.293 | -1.147 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 92.645 | 55.278 | 114.200 | 73.686 | 33.176 |
| 價值變動淨收益/利潤總額(%) | 0.868 | -3.402 | -19.703 | -11.570 | -303.115 |
| 營業外收支淨額/利潤總額(%) | 4.712 | 1.951 | 5.528 | 5.864 | 12.800 | 償債能力分析 |
| 流動比率 (X) | 4.365 | 3.982 | 3.596 | 4.299 | 5.072 |
| 速動比率 (X) | 4.065 | 3.714 | 3.296 | 3.960 | 4.650 |
| 資產負債率 (%) | 15.430 | 15.802 | 17.879 | 16.011 | 13.732 |
| 帶息債務/全部投入資本 (%) | 0.588 | 2.629 | 1.375 | 5.182 | 6.808 |
| 股東權益/帶息債務 (%) | 16,125.604 | 3,543.159 | 6,750.464 | 1,756.515 | 1,342.007 |
| 股東權益/負債合計 (%) | 546.091 | 530.655 | 455.539 | 520.916 | 621.573 |
| 利息保障倍數 (X) | 50.036 | 51.560 | 16.610 | 22.283 | 1.696 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 50.978 | 41.324 | 31.912 | 34.293 | 41.732 |
| 存貨周轉天數 (天) | 101.666 | 111.232 | 109.866 | 123.943 | 97.300 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 24/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
